Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective
At the current negotiated price, evolocumab 140 mg Q2W is the most cost-effective PCSK9 inhibitor regimen for Chinese patients with hypercholesterolemia or at high cardiovascular risk when added to statin therapy. Alirocumab 75 mg Q2W and tafolecimab 150 mg Q2W also represent cost-effective alternatives. These findings provide important evidence to support clinical decision-making and optimize resource allocation in China.
Authors
- Qingfeng He (ORCID: https://orcid.org/0000-0001-5795-1550)
- Xu Deng
- Zhen Feng (ORCID: https://orcid.org/0000-0003-4090-5966)
- Mengwen Feng (ORCID: https://orcid.org/0000-0003-3519-8830)
- Xinyue Zhang (ORCID: https://orcid.org/0000-0002-5908-4478)
- Tao Wang (ORCID: https://orcid.org/0000-0001-9845-3988)
- Dandan Hu
Institutions
- Xuzhou Medical College (CN)
- Fudan University (CN)
- Xuzhou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fphar.2025.1708701
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00